Alumis Inc
ALMS24.800USD
-1.520-5.78%
Handelsschluss 03/27, 16:00（ET）Kurse um 15 Minuten verzögert
1.29BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Alumis Inc Unternehmen
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Alumis Inc Informationen
BörsenkürzelALMS
Name des UnternehmensAlumis Inc
IPO-datumJun 28, 2024
CEOBabler (Martin)
Anzahl der mitarbeiter168
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse280 East Grand Avenue
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16502316625
Websitehttps://www.alumis.com/
BörsenkürzelALMS
IPO-datumJun 28, 2024
CEOBabler (Martin)
Führungskräfte von Alumis Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.49K
+3.65%
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+54.90%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
4.04K
-530.42%
Dr. David M. Goldstein, Ph.D.
Dr. David M. Goldstein, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Ms. Sara Klein
Ms. Sara Klein
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
110.49K
+3.65%
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+54.90%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
4.04K
-530.42%
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.07M
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Feb 19
Aktualisiert: Thu, Feb 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Foresite Capital Management, LLC
13.15%
Ayur Maya Capital Management Company, L.P.
12.29%
Samsara BioCapital, LLC
5.15%
VenBio Partners LLC
3.75%
BlackRock Institutional Trust Company, N.A.
3.34%
Andere
62.32%
Aktionäre
Aktionäre
Anteil
Foresite Capital Management, LLC
13.15%
Ayur Maya Capital Management Company, L.P.
12.29%
Samsara BioCapital, LLC
5.15%
VenBio Partners LLC
3.75%
BlackRock Institutional Trust Company, N.A.
3.34%
Andere
62.32%
Aktionärstypen
Aktionäre
Anteil
Private Equity
30.09%
Hedge Fund
13.00%
Investment Advisor
12.68%
Investment Advisor/Hedge Fund
7.54%
Venture Capital
7.30%
Research Firm
0.96%
Individual Investor
0.62%
Bank and Trust
0.11%
Pension Fund
0.02%
Andere
27.69%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
211
79.11M
81.97%
+900.81K
2025Q3
210
78.21M
82.24%
-347.38K
2025Q2
186
78.54M
55.16%
+26.45M
2025Q1
129
40.48M
86.71%
-471.52K
2024Q4
110
40.33M
76.60%
+5.09M
2024Q3
85
35.23M
67.43%
+3.39M
2024Q2
30
30.28M
0.00%
+30.28M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Foresite Capital Management, LLC
10.61M
10.91%
+580.09K
+5.79%
Nov 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.57%
-1.00
-0.00%
Sep 30, 2025
Samsara BioCapital, LLC
5.13M
5.28%
+333.62K
+6.95%
Nov 20, 2025
VenBio Partners LLC
4.62M
4.75%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.79M
3.9%
-17.42K
-0.46%
Sep 30, 2025
The Vanguard Group, Inc.
4.03M
4.15%
+625.40K
+18.37%
Sep 30, 2025
Cormorant Asset Management, LP
2.15M
2.21%
--
--
Sep 30, 2025
Nextech Invest, Ltd.
2.92M
3%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil0.09%
iShares Micro-Cap ETF
Anteil0.05%
Invesco Nasdaq Biotechnology ETF
Anteil0.05%
iShares Biotechnology ETF
Anteil0.03%
iShares Russell 2000 Value ETF
Anteil0.03%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.03%
ProShares Hedge Replication ETF
Anteil0.02%
iShares Russell 2000 ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
